Keyron is a UK- and US-based, preclinical-stage medical device and technology platform company aimed at a highly effective treatment of metabolic diseases. Keyron’s patented ForePass® is an innovative medical device designed to safely reverse type-2 diabetes, as well as NASH, and obesity. The company has already demonstrated a full reversal of insulin resistance in animal studies, and recently published the results in The Lancet EBioMedicine. Keyron has upcoming clinical trials in South America and aims to then carry out further clinical trials in the USA. Its founders, directors, advisors and investors include some of the most well-known and cited professors and KOLs worldwide in the metabolic diseases space. The company is backed by multiple institutional investors based in the USA and EMEA. Keyron is currently fundraising for a $7.5m Series A investment round. Please contact our CEO, Carl D. Francis (c.francis@keyron.com) for investment enquiries. Disclaimer: This is not a solicitation of investment.
View Top Employees from Keyron Medical TechnologyWebsite | http://www.keyron.com |
Revenue | $3 million |
Employees | 9 (4 on RocketReach) |
Founded | 2016 |
Address | 57a Epirus Road Fulham Broadway, London, Greater London SW6 7UR, GB |
Technologies |
JavaScript,
HTML,
PHP
+6 more
(view full list)
|
Industry | Medical Equipment Manufacturing, Manufacturing General, Manufacturing |
SIC | SIC Code 38 Companies, SIC Code 384 Companies |
NAICS | NAICS Code 33 Companies, NAICS Code 339 Companies |
Looking for a particular Keyron Medical Technology employee's phone or email?
The Keyron Medical Technology annual revenue was $3 million in 2024.
Michael Holder is the Board Member of Keyron Medical Technology.
4 people are employed at Keyron Medical Technology.
Keyron Medical Technology is based in London, Greater London.
The NAICS codes for Keyron Medical Technology are [33, 339].
The SIC codes for Keyron Medical Technology are [38, 384].